Non-bacterial thrombotic endocarditis epidemiology and demographics: Difference between revisions

	non-bacterial thrombotic endocarditis
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating non-bacterial thrombotic endocarditis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
X-ray
Echocardiography and Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Non-bacterial thrombotic endocarditis epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Non-bacterial thrombotic endocarditis epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Non-bacterial thrombotic endocarditis epidemiology and demographics
CDC on Non-bacterial thrombotic endocarditis epidemiology and demographics
Non-bacterial thrombotic endocarditis epidemiology and demographics in the news
Blogs on Non-bacterial thrombotic endocarditis epidemiology and demographics
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Non-bacterial thrombotic endocarditis epidemiology and demographics

Revision as of 13:05, 10 July 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]

The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Patients of all age groups may develop [disease name].
The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
[Chronic disease name] is usually first diagnosed among [age group].
[Acute disease name] commonly affects [age group].

There is no racial predilection to [disease name].
[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

[Disease name] affects men and women equally.
[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

@@ Line 42: / Line 42: @@
 ===Developing Countries===
-Nonbacterial thrombotic endocarditis (NBTE) is a rare condition most often found postmortem with rates in autopsy series ranging from 0.9 to 1.6 percent [1-6]. It has been reported in every age group, most commonly affecting patients between the fourth and eighth decades of life with no sex predilection [1,7-9]. Patients with advanced malignancy and those with systemic lupus erythematosus are the most common populations affected by NBTE.
+<br />
-One autopsy series reported that, compared to the general population, patients with underlying malignancy have a higher rate of NBTE (1.25 versus 0.2 percent) [2,3]. When compared to other malignancies, higher rates were reported in those with adenocarcinoma (eg, lung, colon, ovary, biliary and prostate) (2.7 versus 0.47 percent) with the highest rates observed in patients with mucin-secreting and pancreatic adenocarcinoma (10 percent) [3,7,10].
-In patients with systemic lupus erythematosus, observational studies using transthoracic echocardiography have reported prevalence rates of 6 to 11 percent, with higher rates (43 percent) observed when the more sensitive transesophageal echocardiography was performed
 ==References==
 {{Reflist|2}}